Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose study of OMD-001 in healthy adult volunteers
jRCT2071200085Phase 1Completed
- Sponsor
- Otsuka Medical Devices
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 5-aminolevulinic acid in adult T-cell leukemia-lymphoma (ATLL), sponsored by Otsuka Medical Devices. Primary endpoints: Pharmacokinetics of OMD-001 (5-aminolevulinic acid) and Safety and tolerability of OMD-001. Started Jan 2021; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCT2071200085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200085.